• BioMark Diagnostics Inc. (BUX) has provided updates regarding the ongoing clinical trials using its liquid biopsy test for early cancer detection
  • Enrollment for its lung cancer screening study has exceeded 1000 participants in less than one year
  • It also recruited its first international patient recruited as part of a European prospective lung cancer screening trial in France called the ILYAD study
  • The company signed a collaborative research agreement with an Indian university
  • Lastly, the company intends to validate the test as a laboratory-developed test within the next year
  • BioMark Diagnostics Inc. (BUX) is unchanged, trading at $0.23 per share as of 10:59 a.m. EST

BioMark Diagnostics Inc. (BUX) has provided updates regarding the ongoing clinical trials using its liquid biopsy test for early cancer detection.

BioMark is a liquid biopsy company developing a molecular diagnostics technology platform that uses large-scale cell studies (metabolomics) and machine learning algorithms for new cancer diagnostics and to improve cancer prognosis. Its technology can also be used for measuring response to treatment.

The company stated that enrollment for its lung cancer screening study has exceeded 1000 participants in less than one year. The screening will combine BioMark’s metabolomics liquid biopsy test with traditional screening methods to help at-risk patients get access to an accurate and accessible lung cancer screening program.

BioMark also announced it has recruited its first international patient recruited as part of a European prospective lung cancer screening trial in France called the ILYAD study. The test being developed from this study would screen nearly four million eligible individuals aged between 50 to 75 and have a history of heavy smoking.

Additionally, BioMark recently signed a collaborative research agreement with the Delhi Pharmaceutical Sciences and Research University in India and is currently designing a clinical protocol to evaluate a cost-effective, highly sensitive and easy-to-deploy lung cancer screening platform.  

Lastly, the company intends to validate the test as a laboratory-developed test. The test will be available through its Quebec-based laboratory within nine to 12 months.

BioMark Diagnostics Inc. (BUX) is unchanged, trading at $0.23 per share as of 10:59 a.m. EST.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.